These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32940969)

  • 1. Drug development for cystic fibrosis.
    Sanders DB; Chmiel JF
    Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S10-S22. PubMed ID: 32940969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advancing clinical development pathways for new CFTR modulators in cystic fibrosis.
    Mayer-Hamblett N; Boyle M; VanDevanter D
    Thorax; 2016 May; 71(5):454-61. PubMed ID: 26903594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entering the era of highly effective modulator therapies.
    Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC
    Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
    Cuyx S; De Boeck K
    Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
    Southern KW; Patel S; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Building global development strategies for cf therapeutics during a transitional cftr modulator era.
    Mayer-Hamblett N; van Koningsbruggen-Rietschel S; Nichols DP; VanDevanter DR; Davies JC; Lee T; Durmowicz AG; Ratjen F; Konstan MW; Pearson K; Bell SC; Clancy JP; Taylor-Cousar JL; De Boeck K; Donaldson SH; Downey DG; Flume PA; Drevinek P; Goss CH; Fajac I; Magaret AS; Quon BS; Singleton SM; VanDalfsen JM; Retsch-Bogart GZ
    J Cyst Fibros; 2020 Sep; 19(5):677-687. PubMed ID: 32522463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic fibrosis: a model system for precision medicine.
    Martiniano SL; Sagel SD; Zemanick ET
    Curr Opin Pediatr; 2016 Jun; 28(3):312-7. PubMed ID: 27031658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view.
    De Boeck K; Lee T; Amaral M; Drevinek P; Elborn JS; Fajac I; Kerem E; Davies JC
    J Cyst Fibros; 2020 Sep; 19(5):688-695. PubMed ID: 32527602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
    Lommatzsch ST; Taylor-Cousar JL
    Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations for the Conduct of Clinical Trials with Antiinflammatory Agents in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report.
    Torphy TJ; Allen J; Cantin AM; Konstan MW; Accurso FJ; Joseloff E; Ratjen FA; Chmiel JF;
    Ann Am Thorac Soc; 2015 Sep; 12(9):1398-406. PubMed ID: 26146892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
    Burgener EB; Moss RB
    Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
    Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
    Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging therapies in cystic fibrosis.
    Anderson P
    Ther Adv Respir Dis; 2010 Jun; 4(3):177-85. PubMed ID: 20530065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators.
    Ponzano S; Nigrelli G; Fregonese L; Eichler I; Bertozzi F; Bandiera T; Galietta LJV; Papaluca M
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29653946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy among cystic fibrosis women in the era of CFTR modulators.
    Heltshe SL; Godfrey EM; Josephy T; Aitken ML; Taylor-Cousar JL
    J Cyst Fibros; 2017 Nov; 16(6):687-694. PubMed ID: 28190780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and adverse effects of drugs used to treat adult cystic fibrosis.
    Chopra R; Paul L; Manickam R; Aronow WS; Maguire GP
    Expert Opin Drug Saf; 2015 Mar; 14(3):401-11. PubMed ID: 25604518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis.
    Talwalkar JS; Koff JL; Lee HB; Britto CJ; Mulenos AM; Georgiopoulos AM
    Psychosomatics; 2017; 58(4):343-354. PubMed ID: 28576305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on new and emerging therapies for cystic fibrosis.
    Hudock KM; Clancy JP
    Expert Opin Emerg Drugs; 2017 Dec; 22(4):331-346. PubMed ID: 29264936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
    Kuk K; Taylor-Cousar JL
    Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.